Wild animals, pets, zoo animals and mammals of veterinary importance heavily suffer from trypanosomiasis. Drugs with serious side effects are currently mainstay of therapies used by veterinarians. Trypanosomiasis is caused by Trypanosoma sp. leading to sleeping sickness in humans. Surface modified (hydrophobic and lipophilic) amorphous nanoporous silica molecules could be effectively used as therapeutic drug for combating trypanosomiasis. The amorphous nanosilica was developed by top-down approach using volcanic soil derived silica (Advasan; 50- 60 nm size with 3-10 nm inner pore size range) and diatomaceous earth (FS; 60-80 nm size with 3-5 nm inner pore size range) as source materials. According to WHO and USDA standards amorphous silica has long been used as feed additives for several veterinary industries and considered to be safe for human consumption. The basic mechanism of action of these nanosilica molecules is mediated by the physical absorption of HDL components in the lipophilic nanopores of nanosilica. This reduces the supply of the host derived cholesterol, thus limiting the growth of the Trypanosoma sp. in vivo.
Deep Dive into Control of rodent sleeping sickness disease by surface functionalized amorphous nanosilica.
Wild animals, pets, zoo animals and mammals of veterinary importance heavily suffer from trypanosomiasis. Drugs with serious side effects are currently mainstay of therapies used by veterinarians. Trypanosomiasis is caused by Trypanosoma sp. leading to sleeping sickness in humans. Surface modified (hydrophobic and lipophilic) amorphous nanoporous silica molecules could be effectively used as therapeutic drug for combating trypanosomiasis. The amorphous nanosilica was developed by top-down approach using volcanic soil derived silica (Advasan; 50- 60 nm size with 3-10 nm inner pore size range) and diatomaceous earth (FS; 60-80 nm size with 3-5 nm inner pore size range) as source materials. According to WHO and USDA standards amorphous silica has long been used as feed additives for several veterinary industries and considered to be safe for human consumption. The basic mechanism of action of these nanosilica molecules is mediated by the physical absorption of HDL components in the lipoph
Control of rodent sleeping sickness disease by surface functionalized amorphous
nanosilica
Dipankar Seth1, 3, Mritunjay Mandal2, Nitai Debnath1, Ayesha Rahman1, N. K. Sasmal2, Sunit
Mukhopadhyaya3, and Arunava Goswami1
1Biological Sciences Division, Indian Statistical Institute, 203 B.T. Road, Calcutta- 700 108, West Bengal,
India.
2Department of Veterinary Parasitology and 3Department of Veterinary Pathology, West Bengal University
of Animal and Fisheries Sciences, 37 Kshudiram Bose Sarani, Calcutta 700 037, West Bengal, India.
*To whom correspondence should be addressed. E-mail: agoswami@isical.ac.in (A.G.)
Wild animals, pets, zoo animals and mammals of veterinary importance heavily suffer from
trypanosomiasis1. Drugs with serious side effects are currently mainstay of therapies used by
veterinarians. Trypanosomiasis is caused by Trypanosoma sp. leading to sleeping sickness in
humans. Surface modified (hydrophobic and lipophilic) amorphous nanoporous silica molecules
could be effectively used as therapeutic drug for combating trypanosomiasis. The amorphous
nanosilica was developed by top-down approach using volcanic soil derived silica (Advasan; 50-
60 nm size with 3-10 nm inner pore size range) and diatomaceous earth (FS; 60-80 nm size with
3-5 nm inner pore size range) as source materials2-5. According to WHO and USDA standards
amorphous silica has long been used as feed additives for several veterinary industries and
considered to be safe for human consumption. The basic mechanism of action of these nanosilica
molecules is mediated by the physical absorption of HDL components in the lipophilic nanopores
of nanosilica. This reduces the supply of the host derived cholesterol, thus limiting the growth of
the Trypanosoma sp. in vivo.
Parasites like Trypanosoma evansi isolated from naturally infected horses were artificially
infected into albino mice. The infection causes 100% mortality in mice within 72 ± 24 hours post
infection. Incidentally mice with T. evansi have also been used as model systems for studying
human trypanosomiasis. Serum derived high-density lipoprotein (HDL) could kill Trypanosoma
sp. via formation of anion-selective pores in the lysosomal membrane of parasite. Depletion of
host HDL is critical for proliferation of T. evansi6-10. We demonstrate in this research paper that
Advasan nanosilica could be effectively used as novel drugs for treatment of rodent
trypanosomiasis.
21 day old homozygous albino male mice bred at the mouse facility of West Bengal University of
Animal and Fisheries Sciences were artificially infected with T. evansi and nanosilica (Advasan
and FS) were given as oral dose 1 day post infection. After 72±24 hours post infection, 100%
control infected mice died. 100% Advasan nanosilica treated mice survived 192 ± 24 hours
(period of observation: 216 hours), whereas FS nanosilica treated mice survived for 120±24
hours. Post-mortems were done for studying gross pathological changes.
Nanosilica treated T. evansi
infected mice serum (mgm / dl)
Cholesterol Types
Control mice
Serum
(mgm / dl)
T. evansi
Infected mice
serum (mgm /
dl)
FS
Advasan
Serum Cholesterol
289 ± 6.23
130 ± 8.03
208 ± 5.25
203 ± 3.35
Serum HDL Cholesterol
46 ± 5.03
29 ± 0.63
39 ± 1.13
41 ± 1.86
Serum LDL Cholesterol
194 ± 6.27
71 ± 1.67
154 ± 3.43
134 ± 7.13
Serum VLDL Cholesterol
49 ± 2.09
30 ± 1.04
15 ± 1.08
28 ± 4.76
Serum Triglycerides
247 ± 4.08
150 ± 5.66
78 ± 8.02
139 ± 5.47
Table 1 legend. The different serum cholesterol components as well as the total content were measured 72
hours post infection. In T. evansi infected mice serum, significant decrease in the amount of the HDL was
observed. On application of nanosilica (0.025 mg/ ml) HDL levels were found to be near normal levels.
Table 1 shows that during the course of the T. evansi infection process all the serum cholesterol
components decrease. HDL is the most notable amongst them. But after the administration of the
lipophilic nanosilica at the particular dose mentioned, the levels of HDL came back to the normal
physiological level. This is essential for the quick recovery of the mice to normal health. The
application of higher doses of the nanosilica depletes the cholesterol level completely and
impedes the process of recovery of the mice (data not shown). As cholesterol is necessary for a
number of normal physiological processes, maintenance of the requisite physiological level has to
be taken into consideration while designing the drug dosage.
Table 1 also shows that FS nanosilica treatment could bring the HDL level back to normal, but it
also decreased VLDL level in infected mice to a very low level. As VLDL is necessary is
necessary for normal body functions, therefore mice died early out of secondary reasons in case
of FS nanosilica treatment.
We found that 100% of the infected mice (n=18) treated with nanosilic
…(Full text truncated)…
This content is AI-processed based on ArXiv data.